NCT04050293: Therapy for Migraine Prevention in Children 6-11 Years of Age |
|
|
| Terminated | 4 | 26 | US | SPN-538, Placebo | Supernus Pharmaceuticals, Inc. | Migraine Disorders, Headache Disorders | 05/24 | 05/24 | | |
| Recruiting | N/A | 24 | US | Semaglutide, Glucagon-like peptide-1 receptor (GLP1-R) agonist, Wegovy, Phentermine-Topiramate combination, Qsymia, Phentermine, Lomaira, Adipex-P, Tirzepatide, Mounjaro, Zepbound, GIP/GLP-1 RA, Topiramate, Topamax, Trokendi XR, Qudexy XR, Diethylpropion, Tenuate, Diethylcathinone, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda, Victoza | Louisiana State University Health Sciences Center in New Orleans, Tulane University, Pennington Biomedical Research Center, Ochsner Health System | Obesity | 12/24 | 03/25 | | |
